These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 26521923)

  • 1. GRP78 knockdown does not affect cytotoxicity of cisplatin in ovarian cancer cells.
    Kullmann M; Kotz S; Hellwig M; Kalayda GV; Metzger S; Jaehde U
    Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1038-40. PubMed ID: 26521923
    [No Abstract]   [Full Text] [Related]  

  • 2. Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78.
    Li W; Wang W; Dong H; Li Y; Li L; Han L; Han Z; Wang S; Ma D; Wang H
    Oncol Rep; 2014 Jun; 31(6):2525-34. PubMed ID: 24756776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells.
    Wang G; Shang HL; Xie Y; Xiao P; Li XJ; Lin TC; Li GY
    Chin Med J (Engl); 2005 Feb; 118(4):333-6. PubMed ID: 15740674
    [No Abstract]   [Full Text] [Related]  

  • 4. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
    Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
    Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of subcellular localization of extracellular signal-regulated kinase 1/2 (ERK1/2) for cisplatin resistance.
    Dilruba S; Michaelis M; Cinatl J; Kalayda GV
    Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1041-5. PubMed ID: 26249763
    [No Abstract]   [Full Text] [Related]  

  • 6. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.
    van Jaarsveld MT; Blijdorp IC; Boersma AW; Pothof J; Mathijssen RH; Verweij J; Wiemer EA
    Eur J Cancer; 2013 Jan; 49(2):345-51. PubMed ID: 23041051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
    Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
    Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
    Krieger ML; Eckstein N; Schneider V; Koch M; Royer HD; Jaehde U; Bendas G
    Int J Pharm; 2010 Apr; 389(1-2):10-7. PubMed ID: 20060458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
    Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
    Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
    Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.
    Zhang N; Dai L; Qi Y; Di W; Xia P
    Int J Oncol; 2013 Jun; 42(6):2053-9. PubMed ID: 23592281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
    Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
    Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells.
    Lin Y; Wang Z; Liu L; Chen L
    Lung Cancer; 2011 Mar; 71(3):291-7. PubMed ID: 20599289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
    Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
    Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
    Li Y; Weng DH; Kong FF; Fan LS; Hu Y; Song XH; Xing H; Wang W; Ma D; Wang SX
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jun; 45(6):445-8. PubMed ID: 21029596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.